Anti-Cancer and Anti-Infectious Disease Compositions and Methods for Using Same
OwnerW Michael Kavanaugh, Mary Lee MacKichan +1inventors
InventorsW Michael Kavanaugh, Mary Lee MacKichan, David L. Sloane
Life of this patent
Estimating the term…
Abstract
The present invention provides methods and compositions for treating and/or preventing cancer in a subject via administration of a non-pathogenic virus. The present invention also provides methods and compositions for treating and/or preventing infectious diseases in a subject via administration of a non-pathogenic.
Claims49
1-148. (canceled)
A method of treating or preventing a disease or a symptom of a disease in an animal comprising administering to said animal an amount of a composition comprising a non-pathogenic, insect-specific virus effective to treat or prevent the disease or disease symptom in said animal.
A method of inducing an immune response in an animal comprising administering to said animal an amount of a composition comprising an inactive non-pathogenic, insect-specific virus effective to induce an immune response in said animal.
A method of causing cell death in a cell comprising administering a composition comprising an amount of a non-pathogenic, insect-specific virus to said cell effective to cause cell death in said cell.
A method of causing cell death in a population of cells comprising contacting a composition comprising an amount of a non-pathogenic, insect-specific virus to a portion of said population of cells effective to cause cell death in said population of cells.
A method of predicting in vivo anti-tumor activity of a compound comprising:
- a) contacting the compound with tumor cells and peripheral blood mononuclear cells;
- and
- b) measuring cell death of said tumor cells;
- wherein compounds that cause cell death of contacted tumor cells are predicted in be active in vivo.
A composition comprising a non-pathogenic, insect-specific virus and a pharmaceutically acceptable carrier.
A composition comprising an inactivated non-pathogenic, insect-specific virus, at least one antigen, wherein the antigen is distinct from the inactivated non-pathogenic, insect-specific virus, at least one adjuvant, and a pharmaceutically acceptable carrier.
A composition comprising an adjuvant composition, said adjuvant composition comprising an inactivated non-pathogenic, insect-specific virus, at least one antigen, wherein said antigen is distinct from the adjuvant composition, and further wherein said immunostimulating composition is capable of increasing the immune response to the antigen.
A composition comprising a non-pathogenic, insect-specific virus, one or more peripheral blood mononuclear cells (PBMCs), and a pharmaceutically acceptable carrier.
A process for preparing an anticancer or anti-infectious disease composition comprising a non-pathogenic, insect-specific virus, said process comprising:
- (a) exposing the non-pathogenic, insect-specific virus to a first inactivator effective to inactivate an active virus;
- (b) exposing the non-pathogenic, insect-specific virus to a second inactivator effective to inactivate an active virus;
- (c) combining said non-pathogenic, insect-specific virus with one or more pharmaceutically acceptable carriers or excipients;
- and
- (d) confirming inactivity of non-pathogenic, insect-specific virus in an in vitro assay.
Dependencies are inferred from the claim text.